Health and Healthcare Systems

Here’s why antimicrobial resistance matters, according to the UK’s superbug expert

View of orange pills.

Each year, AMR directly kills about 1.3 million people worldwide. Image: Unsplash/victoriabcphotographer

Charlotte Edmond
Senior Writer, Forum Agenda
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on Health and Healthcare Systems?
The Big Picture
Explore and monitor how Health and Healthcare is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Health and Healthcare

  • Each year antimicrobial resistance kills about 1.3 million people worldwide, and the problem is getting worse.
  • Industry and governments need to come together to help solve the issue, Dame Sally Davies says.
  • Davies is a member of the World Economic Forum’s Global Future Council on the Future of Tackling Antimicrobial Resistance, an initiative dedicated to finding new approaches to tackling superbugs.

“People are suffering and dying because they have caught untreatable infections. We’ve got to stop this.”

As the UK government’s Special Envoy on Antimicrobial Resistance, Dame Sally Davies is concerned about the growing threat of superbugs and the burden they are placing on healthcare systems.

Antimicrobial resistance (AMR) is when bacteria, viruses, fungi and parasites stop responding to the drugs used to treat and prevent them. These strains are often referred to as ‘superbugs’, and they have been declared as one of the top 10 global public health threats facing humanity by the World Health Organization (WHO).

Each year, AMR directly kills about 1.3 million people worldwidemore deaths than HIV/AIDS or malaria – and is associated with 5 million more deaths.

“AMR is out of control – and it’s getting worse,” Davies says.

Infographic illustrating the predicted mortality from antimicrobial-resistant infections versus today's common causes of deaths.
A growing number of deaths will be caused by antimicrobial resistance. Image: Statista

AMR – more than a human health issue

Although we often look at AMR through the lens of human health, it is a far bigger problem, Davies says. AMR is a ‘One Health’ issue, meaning it affects people, animals and the environment in an interlinked way.

As well as health security, it also impacts the security of our food chains: we use antimicrobials to treat sick animals and plants.

Overuse and misuse of antibiotics and other drugs drives mutations for resistance and leads to the emergence of superbugs. Examples of this include prescriptions given for the wrong issue – like an antibiotic to treat a virus. Or people buying antibiotics rather than being prescribed them. Around the world antibiotics are also used to promote growth in animals.

The problem is then amplified when the treatments contaminate the environment through human and animal waste, or through effluent from factories producing the pharmaceuticals. Increased migration and the climate crisis are also having an impact.

Discover

What is the World Economic Forum doing to improve healthcare systems?

World AMR Awareness Week takes place this year on 18-24 November, with the aim of improving awareness and understanding of AMR, and promoting best practices.

The link between antibiotic misuse and overuse is strongly tied to rising AMR – India has both the highest level of antibiotic consumption and the highest rate of AMR globally.

“[The problem is] aggravated by poor diagnostics and no access to diagnostics in many places, and an empty pipeline of new drugs,” Davies explains. “When I was a young doctor, the microbiologist would say, ‘Oh, Sally, we've got a patient who's got an infection resistant to that antibiotic. Just open the cupboard and get antibiotic Y out’. There were more antibiotics to use, but now the pipeline of new antibiotics is empty, and that's very worrying. We've got to stimulate innovation or we will be lost.”

Infographic illustrating the waterborne and sources of human and animal exposure.
Antimicrobial resistance is introduced to water supplies from animals, humans and agriculture. Image: World Economic Forum

What does AMR look like to health systems?

“The face of AMR is very difficult to find,” says Davies, because doctors and nurses rarely attribute deaths to the superbugs. They are more likely to consider their patient died of pneumonia which was hard to treat, for example.

“So somehow to really galvanize people to move forward on this, we've got to find a face. Imagine living with cystic fibrosis where you repeatedly get infections. Most of them get resistant infections.”

Have you read?

What’s the solution to AMR?

Pressure from health systems to produce masses of antibiotics cheaply to save money has left no money in the system for research, Davies argues. As a result, most of the big pharmaceutical companies have withdrawn from this area, and the biotechs and start-ups with promising or interesting new drugs struggle to sell them on for development.

We need industry and governments to focus on how to sort the market failure, she says. Davies is a member of the World Economic Forum’s Global Future Council on the Future of Tackling Antimicrobial Resistance, an initiative dedicated to finding new approaches to tackling AMR.

Part of solving the problem will be new antibiotics and antivirals, for example, but other solutions may come from helping get rid of resistance once it has developed. Bacteriophages, a virus which infects bacteria, could also be used in future, Davies suggests.

“We need industry and governments to focus on how to sort the market failure. We need the food chain to not use antibiotics for growth promotion and never to use medically critical antibiotics unless an animal is very sick. We need humans to have access to the drugs they need of high quality. Put all of that together with good laboratory diagnostics and we will be a long way to mitigating AMR and saving lives,” she summarizes.

Loading...
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Funding the future: Sustainable financing models to help the fight against antimicrobial resistance

Shyam Bishen

October 10, 2024

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum